Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $396.5 million.

  • Autolus Therapeutics' Total Liabilities rose 1311.46% to $396.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.5 million, marking a year-over-year increase of 1311.46%. This contributed to the annual value of $355.4 million for FY2024, which is 3466.87% up from last year.
  • Per Autolus Therapeutics' latest filing, its Total Liabilities stood at $396.5 million for Q3 2025, which was up 1311.46% from $374.5 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Total Liabilities ranged from a high of $396.5 million in Q3 2025 and a low of $47.0 million during Q2 2021
  • Its 5-year average for Total Liabilities is $217.3 million, with a median of $221.7 million in 2023.
  • As far as peak fluctuations go, Autolus Therapeutics' Total Liabilities plummeted by 3533.25% in 2021, and later surged by 12287.06% in 2023.
  • Autolus Therapeutics' Total Liabilities (Quarter) stood at $92.2 million in 2021, then surged by 107.72% to $191.6 million in 2022, then soared by 37.74% to $263.9 million in 2023, then soared by 34.67% to $355.4 million in 2024, then rose by 11.56% to $396.5 million in 2025.
  • Its Total Liabilities was $396.5 million in Q3 2025, compared to $374.5 million in Q2 2025 and $375.2 million in Q1 2025.